Uncertainty Over the Timing of Approval and Market Size for Anti-Fatigue FOSHU Products
First written in FY2016. 15 of 16 entries say "Restated". Latest entry: FY2024-Q2.
No other company in this theme has enough history to compare yet.
- FY2024-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The uncertainty surrounding the approval timing and market size of antifatigue FOSHU products is disclosed as having no material changes. - FY2024-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The uncertainty surrounding the approval timing and market size of antifatigue FOSHU products is disclosed as having no material changes. - FY2023RestatedAnnual report
「Although the Company plans to continue focusing on obtaining approval to make antifatigue claims for the product, there is no guarantee that approval to make such claims will be obtained.」
The uncertainty surrounding approval of antifatigue FOSHU products, the review period, market size and timing of the contribution to performance continues to be disclosed. - FY2023-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The uncertainty surrounding the approval timing and market size of antifatigue FOSHU products is disclosed as having no material changes. - FY2023-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The uncertainty surrounding the approval timing and market size of antifatigue FOSHU products is disclosed as having no material changes. - FY2022-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The uncertainty surrounding the approval timing and market size of antifatigue FOSHU products is disclosed as having no material changes. - FY2021-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The uncertainty surrounding the approval timing and market size of antifatigue FOSHU products is disclosed as having no material changes. - FY2021-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The uncertainty surrounding the approval timing and market size of antifatigue FOSHU products is disclosed as having no material changes. - FY2020RestatedAnnual report
「Although the Company plans to continue focusing on obtaining approval to make antifatigue claims for the product, there is no guarantee that approval to make such claims will be obtained.」
The uncertainty surrounding approval of antifatigue FOSHU products, the review period, market size and timing of the contribution to performance continues to be disclosed. - FY2020-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The uncertainty surrounding the approval timing and market size of antifatigue FOSHU products is disclosed as having no material changes. - FY2020-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The uncertainty surrounding the approval timing and market size of antifatigue FOSHU products is disclosed as having no material changes. - FY2019-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The uncertainty surrounding the approval timing and market size of antifatigue FOSHU products is collectively disclosed as having no material changes. - FY2019-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The uncertainty surrounding the approval timing and market size of antifatigue FOSHU products is collectively disclosed as having no material changes. - FY2019-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The uncertainty surrounding the approval timing and market size of antifatigue FOSHU products is collectively disclosed as having no material changes. - FY2018RestatedAnnual report
「It is uncertain whether approval will ultimately be obtained. Even if approval is obtained, the system does not specify the period required for review or other such matters, and it is currently difficult to forecast the market size of antifatigue FOSHU products.」
The uncertainty surrounding approval of antifatigue FOSHU products, the review period, market size and timing of the contribution to performance continues to be disclosed. - FY2016First statedAnnual report
「It is uncertain whether approval will ultimately be obtained. Even if approval is obtained, the system does not specify the period required for review or other such matters, and it is currently difficult to forecast the market size of antifatigue FOSHU products.」
The Company states that the approval outcome, review period, market size, and timing and extent of the contribution to performance are uncertain.